Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
Active, not recruiting · NCT03715478 · Registry updated 2025-01-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex | Relapsed and/or Refractory Multiple Myeloma | Active, not recruiting | Phase 1 / Phase 2 | 2025-01-08 | NCT03715478 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Myeloma Research Group | 4 |
| GlaxoSmithKline | 294 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Allan Blair Cancer Centre | Regina | Canada | 4 |
| CancerCare Manitoba | Winnipeg | Canada | 3 |
| Cross Cancer Institute | Edmonton | Canada | 7 |
| Juravinski Cancer Centre | Hamilton | Canada | 11 |
| London Health Sciences Centre | London | Canada | 39 |
| Princess Margaret Cancer Centre | Toronto | Canada | 22 |
| QEII Health Sciences Centre | Halifax | Canada | 4 |
| The Ottawa Hospital | Ottawa | Canada | 27 |
| Vancouver General Hospital | Vancouver | Canada | 19 |